Trial Profile
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Feb 2023 Status changed from recruiting to discontinued.
- 01 Oct 2022 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 01 Oct 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.